BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 19212669)

  • 1. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
    Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.
    Zhao Q; Yu WL; Lu XY; Dong H; Gu YJ; Sheng X; Cong WM; Wu MC
    Chin J Cancer; 2016 Aug; 35(1):82. PubMed ID: 27552844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
    Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
    Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
    Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
    Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
    Stroescu C; Herlea V; Dragnea A; Popescu I
    J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
    Mounajjed T; Zhang L; Wu TT
    Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
    Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
    Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synchronous double cancers of primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a case report and review of the literature.
    Wu C; Bai DS; Jiang GQ; Jin SJ
    World J Surg Oncol; 2014 Nov; 12():337. PubMed ID: 25385169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.
    Ono Y; Hiratsuka Y; Murata M; Takasawa A; Fukuda R; Nojima M; Tanaka S; Osanai M; Hirata K; Sawada N
    Virchows Arch; 2016 Oct; 469(4):417-26. PubMed ID: 27444172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
    Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
    Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
    Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
    Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
    PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence.
    Zhang F; Chen XP; Zhang W; Dong HH; Xiang S; Zhang WG; Zhang BX
    Histopathology; 2008 Jan; 52(2):224-32. PubMed ID: 18184271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.
    Wakizaka K; Yokoo H; Kamiyama T; Ohira M; Kato K; Fujii Y; Sugiyama K; Okada N; Ohata T; Nagatsu A; Shimada S; Orimo T; Kamachi H; Taketomi A
    J Gastroenterol Hepatol; 2019 Jun; 34(6):1074-1080. PubMed ID: 30462849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined hepatocellular-cholangiocarcinoma with stem cell features, ductal plate malformation subtype: a case report and proposal of a new subtype.
    Terada T
    Int J Clin Exp Pathol; 2013; 6(4):737-48. PubMed ID: 23573322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMARCB1/INI1 Is Diagnostically Useful in Distinguishing α-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
    Mochizuki K; Kawai M; Odate T; Tahara I; Inoue T; Kasai K; Nakazawa T; Kondo T
    Anticancer Res; 2018 Dec; 38(12):6865-6868. PubMed ID: 30504402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma.
    Ushiku T; Shinozaki A; Shibahara J; Iwasaki Y; Tateishi Y; Funata N; Fukayama M
    Am J Surg Pathol; 2010 Apr; 34(4):533-40. PubMed ID: 20182341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
    Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
    Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
    Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.